Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

The Novel Clostridial Neurotoxin Produced by Strain IBCA10-7060 Is Immunologically Equivalent to BoNT/HA.

Fan Y, Barash JR, Conrad F, Lou J, Tam C, Cheng LW, Arnon SS, Marks JD.

Toxins (Basel). 2019 Dec 20;12(1). pii: E9. doi: 10.3390/toxins12010009.

2.

Safety and Pharmacokinetics of a Four Monoclonal Antibody Combination Against Botulinum C and D Neurotoxins.

Snow DM, Riling K, Kimbler A, Espinoza Y, Wong D, Pham K, Martinez Z, Kraus CN, Conrad F, Garcia-Rodriguez C, Cobb RR, Marks JD, Tomic MT.

Antimicrob Agents Chemother. 2019 Oct 7. pii: AAC.01270-19. doi: 10.1128/AAC.01270-19. [Epub ahead of print]

3.

Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells.

Takasaka N, Seed RI, Cormier A, Bondesson AJ, Lou J, Elattma A, Ito S, Yanagisawa H, Hashimoto M, Ma R, Levine MD, Publicover J, Potts R, Jespersen JM, Campbell MG, Conrad F, Marks JD, Cheng Y, Baron JL, Nishimura SL.

JCI Insight. 2018 Oct 18;3(20). pii: 122591. doi: 10.1172/jci.insight.122591.

4.

Antibody engineering to improve manufacturability.

Wijesuriya SD, Pongo E, Tomic M, Zhang F, Garcia-Rodriquez C, Conrad F, Farr-Jones S, Marks JD, Horwitz AH.

Protein Expr Purif. 2018 Sep;149:75-83. doi: 10.1016/j.pep.2018.04.003. Epub 2018 Apr 12.

PMID:
29655788
5.

A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes.

Garcia-Rodriguez C, Razai A, Geren IN, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD.

Toxins (Basel). 2018 Mar 1;10(3). pii: E105. doi: 10.3390/toxins10030105.

6.

A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A.

Lou J, Wen W, Conrad F, Meng Q, Dong J, Sun Z, Garcia-Rodriguez C, Farr-Jones S, Cheng LW, Henderson TD, Brown JL, Smith TJ, Smith LA, Cormier A, Marks JD.

Toxins (Basel). 2018 Feb 15;10(2). pii: E84. doi: 10.3390/toxins10020084.

7.

A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes.

Fan Y, Garcia-Rodriguez C, Lou J, Wen W, Conrad F, Zhai W, Smith TJ, Smith LA, Marks JD.

PLoS One. 2017 Mar 21;12(3):e0174187. doi: 10.1371/journal.pone.0174187. eCollection 2017.

8.

Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.

Fan Y, Barash JR, Lou J, Conrad F, Marks JD, Arnon SS.

J Infect Dis. 2016 May 15;213(10):1606-14. doi: 10.1093/infdis/jiv770. Epub 2016 Mar 1.

9.

Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B.

Fan Y, Dong J, Lou J, Wen W, Conrad F, Geren IN, Garcia-Rodriguez C, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD.

Toxins (Basel). 2015 Aug 26;7(9):3405-23. doi: 10.3390/toxins7093405.

10.

Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity.

Fan Y, Geren IN, Dong J, Lou J, Wen W, Conrad F, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD.

PLoS One. 2015 Aug 14;10(8):e0135306. doi: 10.1371/journal.pone.0135306. eCollection 2015.

11.

Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.

Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD.

Mol Cancer Ther. 2012 Jul;11(7):1467-76. doi: 10.1158/1535-7163.MCT-11-1038. Epub 2012 May 7.

12.

Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.

Wang Y, Keck ZY, Saha A, Xia J, Conrad F, Lou J, Eckart M, Marks JD, Foung SK.

J Biol Chem. 2011 Dec 23;286(51):44218-33. doi: 10.1074/jbc.M111.290783. Epub 2011 Oct 14.

13.

A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region.

Dong J, Thompson AA, Fan Y, Lou J, Conrad F, Ho M, Pires-Alves M, Wilson BA, Stevens RC, Marks JD.

J Mol Biol. 2010 Apr 9;397(4):1106-18. doi: 10.1016/j.jmb.2010.01.070. Epub 2010 Feb 6.

14.

Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion.

Conrad F, Zhu X, Zhang X, Chalkley RJ, Burlingame AL, Marks JD, Liu B.

J Mol Med (Berl). 2009 May;87(5):507-14. doi: 10.1007/s00109-009-0446-3. Epub 2009 Feb 14.

15.

Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.

Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, Benz CC, Marks JD, Liu B.

Mol Cancer Ther. 2007 Oct;6(10):2737-46.

16.

Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.

Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD.

J Mol Med (Berl). 2007 Oct;85(10):1113-23. Epub 2007 Jun 7.

PMID:
17554518
17.

Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells.

Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD.

Cancer Res. 2004 Jan 15;64(2):704-10.

Supplemental Content

Loading ...
Support Center